Amarin, a biopharmaceutical company, has announced the outcome of the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee for the use of Vascepa (icosapent ethyl) capsules in the treatment of high ...
The USFDA has approved Amarin supplemental new drug application for Chemport as additional Vascepa active pharmaceutical ingredient supplier. The approval adds to the company's planned expansion of the Vascepa manufacturing supply chain ...
Biopharmaceutical company Amarin has submitted a Supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA), seeking approval for the marketing and sale of its Vascepa(R) (icosapent ethyl) capsules. Vascepa is ...
Tags: Amarin, Vascepa Capsule, FDA
The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to biopharmaceutical company Amarin for its claims related to Vascepa and FDA-approved MARINE indication. The NOA, which is issued based on patent ...
Tags: NOA, Vascepa capsules, biopharmaceutical
The US Patent and Trademark Office (USPTO) has granted a new Patent No. 8,298,554 to Amarin's pharmaceutical composition of ultra pure omega-3 fatty acid product. The patent covers the claims related to application No.12/769,885 for the ...
Tags: ultra pure omega-3 fatty acid product, vascepa capsules, icosapent ethyl
The US Patent and Trademark Office (USPTO) has granted two new patents including Patent No. 8,793,727 and 8,293,728 to Amarin's ultra pure omega-3 fatty acid product. The patents include application No.12/702,889 and 13/349,153 for ...
The United States Patent and Trademark Office (USPTO) has published notification of a notice of allowance for Amarin's patent application titled Highly Stable EPA in a Capsule. A notice of allowance is issued after the USPTO makes a ...
Tags: patent application, USPTO, AMR101